EpiCept has recently analyzed the imaging data from the first eight patients enrolled in the study who had measurable Computed Tomography (CT) perfusion scans. These patients received doses of EPC2407 ranging from 4mg/kg to 13mg/kg in three different cohorts. The results indicated that the disease had stabilized in seven of the eight patients studied. The CT perfusion scan measurements indicated that overall blood perfusion in the tumor decreased with EPC2407 treatment in the second and third cohorts, indicating an effective vascular disruption agent (VDA) dose had been reached.
These data were measured five days after the last dose in a cycle, suggesting a sustained effect after dosing. In addition, the patients with stable disease over several treatment cycles had the greatest decreases in tumor perfusion as well as results indicative of decreased blood flow and decreased blood volume to the tumor, all suggesting a potential anti-tumor response.
Jack Talley, president and CEO of EpiCept, said: “We also are continuing our preparations for a Phase Ib trial for EPC2407 in combination with other chemotherapeutic agents, which we anticipate will commence in late 2008.”